🇺🇸 FDA
Patent

US 12329751

Topical roflumilast formulation having antifungal properties

granted A61KA61K31/137A61K31/201

Quick answer

US patent 12329751 (Topical roflumilast formulation having antifungal properties) held by ARCUTIS BIOTHERAPEUTICS, INC. expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARCUTIS BIOTHERAPEUTICS, INC.
Grant date
Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
40
CPC classes
A61K, A61K31/137, A61K31/201, A61K31/27, A61K31/343